Fbln5, a member of the short fibulins in the fibulin family of extracellular matrix/matricellular proteins, is involved in interactions with components of the basement membrane and extracellular matrix proteins. It plays key roles in endothelial tissues in many vascular diseases and is also important for maintaining the stability of ECM structures, regulating cell proliferation and tumorigenesis [3,4].

Fbln5 is significantly related to the poor prognosis of gastric cancer (GC) patients, with high Fbln5 mRNA levels associated with a poor prognosis and high Fbln5 expression correlated with INFc and N3 lymph node metastasis. Univariate and multivariate analyses showed it as an independent risk factor for GC patient prognosis [1]. In renal clear cell carcinoma (KIRC) in children and young adults, Fbln5 expression was significantly reduced in KIRC tissue compared to normal adjacent tissue. High expression of Fbln5 was associated with a favorable prognosis, and it was potentially involved in immune-related biological processes [2]. In high-grade serous ovarian carcinoma (HGSOC), Fbln5 expression was decreased in cancer samples compared to normal fallopian tube samples, and its reduced expression was associated with an unfavorable prognosis. Overexpression of Fbln5 inhibited ovarian cancer cell migration, invasion, and proliferation in vitro [3].

In conclusion, Fbln5 has important functions in maintaining extracellular matrix stability, cell proliferation, and tumorigenesis. Its abnormal expression is associated with various cancers, such as gastric, renal clear cell, and high-grade serous ovarian carcinomas, highlighting its potential as a prognostic marker and therapeutic target in these disease areas.

References:

1. Bian, Xiulan, Yin, Shengjie, Yin, Xin, Ye, Fei, Zhang, Lei. 2023. Clinical and Biological Significances of FBLN5 in Gastric Cancer. In Cancers, 15, . doi:10.3390/cancers15020553. https://pubmed.ncbi.nlm.nih.gov/36672502/

2. Zhang, Ming, Chen, Feng, Feng, Shaoguang, Zhu, Dongsheng, Zhu, Zhitao. 2024. FBLN5 as One Presumably Prognostic Gene Potentially Modulating Tumor Immune Microenvironment for Renal Clear Cell Carcinoma in Children and Young Adults. In Pharmacogenomics and personalized medicine, 17, 27-40. doi:10.2147/PGPM.S442803. https://pubmed.ncbi.nlm.nih.gov/38264064/

3. Li, Rongrong, Wu, Huan, Jiang, Huiyang, Yang, Ning, Kong, Beihua. 2020. FBLN5 is targeted by microRNA‑27a‑3p and suppresses tumorigenesis and progression in high‑grade serous ovarian carcinoma. In Oncology reports, 44, 2143-2151. doi:10.3892/or.2020.7749. https://pubmed.ncbi.nlm.nih.gov/32901854/

4. Zheng, Lin, Yue, Xinyang, Li, Minhui, Chen, Ruihan, Dong, Honglin. 2022. Contribution of FBLN5 to Unstable Plaques in Carotid Atherosclerosis via mir128 and mir532-3p Based on Bioinformatics Prediction and Validation. In Frontiers in genetics, 13, 821650. doi:10.3389/fgene.2022.821650. https://pubmed.ncbi.nlm.nih.gov/35356421/